EASY BIO (353810) Fundamentals 2026 — P/E 6.0x, Revenue Analysis | SniperIQ
EASY BIO (353810) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩199.5B, trading at ₩6030.00 on the KOE. This SniperIQ fundamentals page covers EASY BIO's valuation (P/E 6.0x, P/B 1.7x), profitability (net margin 6.8%), revenue (₩476.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is EASY BIO's market cap?
EASY BIO (353810) has a market capitalization of approximately ₩199.5B, trading at ₩6030.00 on the KOE. Market cap moves with the live share price.
What is EASY BIO's P/E ratio?
EASY BIO's trailing twelve-month P/E ratio is 6.0x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is EASY BIO?
EASY BIO runs a net profit margin of 6.8%, a gross margin of 26.3%, and an operating margin of 10.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does EASY BIO generate?
EASY BIO reported revenue of ₩476.9B for fiscal year 2025, with net income of ₩27.8B and earnings per share (EPS) of 840. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does EASY BIO pay a dividend?
EASY BIO offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is EASY BIO financially healthy?
EASY BIO carries a debt-to-equity ratio of 1.43x and a current ratio of 1.23x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is EASY BIO a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For EASY BIO (353810) the key facts are: market cap ₩199.5B, P/E 6.0x, revenue ₩476.9B, 52-week range 5100-8560. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track EASY BIO's full fundamentals live
Get EASY BIO's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.